Key result
C4 EV71 vaccines elicited good cross-neutralizing antibody titers against 10 sub-genotypes in infants and children (MAX/MIN ratio 1.8-3.4), comparable to naturally infected patients (2.8).
Why the study?
The use of vaccines eliciting cross-neutralizing antibodies against different circulating EV71 sub-genotypes is important for preventing severe hand-foot-and-mouth disease outbreaks.
Does the C4 EV71 vaccine induce cross-neutralizing antibodies against different EV71 sub-genotypes in rats and humans?
Does the C4 EV71 vaccine induce cross-neutralizing antibodies against different EV71 sub-genotypes in rats and humans?
C4 EV71 vaccines can provide broad cross-neutralizing antibody responses against multiple EV71 sub-genotypes, suggesting potential global protection against HFMD.
Observed cross-neutralization differences among EV71 sub-genotypes in rats warrant caution for broad vaccine protection; leaves open optimal strain selection for human trials.
Enterovirus A-71 (EV71) is a global, highly contagkkious pathogen responsible for severe cases of hand-food-mouth-disease (HFMD). The use of vaccines eliciting cross neutralizing antibodies (NTAbs) against the different circulating EV71 sub-genotypes is important for preventing HFMD outbreaks. Here, we tested the cross-neutralizing activities induced by EV71 genotype/sub-genotype A, B0-B4, C1, C2, C4, and C5 viruses using rats. Differences were noted in the cross-neutralization of the 10 sub-genotypes tested but there were generally good levels of cross-neutralization except against genotype A virus, against which neutralization antibody titres (NTAb) where the lowest with NTAbs being the highest against sub-genotype B4. Moreover, NTAb responses induced by C4, B4, C1, and C2 viruses were homogenous, with values of maximum/minimum NTAb ratios (MAX/MIN) against all B and C viruses ranging between 4.0 and 6.0, whereas MAX/MIN values against B3 and A viruses were highly variable, 48.0 and 256.0, respectively. We then dissected the cross-neutralizing ability of sera from infants and children and rats immunized with C4 EV71 vaccines. Cross-neutralizing titers against the 10 sub-genotypes were good in both vaccinated infants and children and rats with the MAX/MIN ranging from 1.8-3.4 and 5.1-7.1, respectively, which were similar to those found in naturally infected patients (2.8). Therefore, we conclude that C4 EV71 vaccines can provide global protection to infants and children against HFMD caused by different sub-genotypes.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied Hand-foot-mouth disease (HFMD) / Enterovirus A-71 (EV71) infection. C4 EV71 vaccine vs. Naturally infected patients was evaluated on Cross-neutralizing antibody titers (MAX/MIN NTAb ratios) against 10 EV71 sub-genotypes. C4 EV71 vaccines elicited good cross-neutralizing antibody titers against 10 sub-genotypes in infants and children (MAX/MIN ratio 1.8-3.4), comparable to naturally infected patients (2.8).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: